Mission

We are passionately focused on reducing the global Afib epidemic and healing the lives of those affected.

Values

We work to heal the lives of Patients, empower our People, and collaborate with our Partners to reduce the burden of Afib worldwide.

PATIENTS

Our ﬁrst responsibility is to put patients first. We lead rigorous clinical science to determine the safest, most eﬀective approaches and treatments. Our commitment to education generates consistent, predictable practices and standards of care. We undertake relentless innovation to reveal new ideas that improve the experience of providers and supports the care they deliver to each patient.

PEOPLE

Our people act with unwavering integrity and transparency in all we do. While honoring the dignity of each person, we foster collaboration to achieve excellence across all areas. We sustain a humble culture of gratitude for each other and the good that we can bring to the world.

PARTNERS

We are committed to delivering the highest quality and most efficient solutions to benefit our partners, including care providers, customers, and shareholders. We strive to understand their needs and to offer the products, services, and business value that meet those needs.

Key Facts

Served over 350,000 patients with ablation
Over 2,500 healthcare professionals trained
Products sold in over 50 countries
Over 200,000 AtriClip devices sold worldwide
138 issued patents (USA)
More than 700 employees worldwide
Headquartered near Cincinnati, Ohio
Developed first and only device approved by FDA for surgical treatment of persistent and longstanding persistent Afib

Our Quality Policy

AtriCure’s quality policy represents its commitment to complying with quality standards and regulations.

AtriCure Lumitip -Model MID1 and GPD1 -Dissection System

Features